SCHEMBL2933374

SCHEMBL2933374

CC(C)C[CH]NC(=O)[C@@H](NC(=O)c1cnc(-c2ccccc2)cn1)[C@@H](C)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 6/20 0.48
PSMB1 P20618 4/20 0.48
PSMB8 P28062 4/20 0.48
PSMB9 P28065 4/20 0.48
PSMB10 P40306 4/20 0.48
PSMB2 P49721 4/20 0.48
CYP3A4 P08684 2/20 0.48
ELANE P08246 2/20 0.48
CTSG P08311 2/20 0.48
CMA1 P23946 2/20 0.48
CNR2 P34972 1/20 0.39
GRN P28799 1/20 0.38
SORT1 Q99523 1/20 0.38
MME P08473 1/20 0.38
SLC16A3 O15427 1/20 0.37
CNR1 P21554 1/20 0.36
LONP1 P36776 4/20 0.36
PSMB11 A5LHX3 3/20 0.36
PSMA7 O14818 3/20 0.36
PSMA1 P25786 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934898 0.86 CTSA (0.47) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL2927875 0.84 ELANE (0.47) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL2932157 0.84 PSMB5 (0.52) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL608032 0.84 ELANE (0.67) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL2933382 0.82 CYP3A4 (0.48) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL2931761 0.82 CTSA (0.47) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL2926221 0.81 GRN (0.55) PSMB5GRNSORT1
SCHEMBL2932636 0.81 EGLN1 (0.41) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL2934071 0.80 PSMB5 (0.73) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL2934925 0.80 KDM4E (0.47) PSMB5PSMB1PSMB8PSMB9PSMB10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US claimed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US claimed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189806-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 PSMB5 2/4885PSMB1 4/4885PSMB8 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.